Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745069 | 0.90 | TNIK (0.57) | CYP19A1PGRTNIKGPR55CYP11B2 | |
| SCHEMBL801469 | 0.80 | GPR55 (0.54) | GPR55CYP11B2CYP11B1BACE1 | |
| SCHEMBL783391 | 0.78 | CYP11B2 (0.45) | GPR55CYP11B2CYP11B1 | |
| SCHEMBL783358 | 0.77 | CYP11B2 (0.49) | TNIKGPR55CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL782507 | 0.77 | CYP11B2 (0.48) | TNIKGPR55CYP11B2 | |
| SCHEMBL768881 | 0.77 | MAPK14 (0.58) | CYP19A1CYP11B2CYP11B1CYP17A1CYP1A2 | |
| SCHEMBL782795 | 0.76 | CYP11B2 (0.47) | GPR55CYP11B2CYP11B1BACE1 | |
| SCHEMBL783487 | 0.76 | KCNJ1 (0.51) | TNIKGPR55CYP11B2CYP11B1 | |
| SCHEMBL20172639 | 0.76 | GPR55 (0.46) | GPR55 | |
| SCHEMBL782587 | 0.76 | CYP11B2 (0.52) | CYP19A1TSPOGPR55CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CYP19A1 36/4885PGR 449/4885TNIK 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.